Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
Source: SeekingAlpha
2026-01-08 11:44:52 ET
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria January 8, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
Jasper Therapeutics Inc.
NASDAQ: JSPR
JSPR Trading
9.09% G/L:
$1.44 Last:
131,861 Volume:
$1.36 Open:
JSPR Latest News
February 24, 2026 04:30:00 pm
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
January 08, 2026 07:00:00 am
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
January 07, 2026 04:30:00 pm
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
JSPR Stock Data
$36,659,091
21,939,487
1.06%
33
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
